Marktanalyse - Dengue Fever - Pipeline Review, H2 2016

Global Markets Direct
12.2016
195 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Dengue Fever - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever — Pipeline Review, H2 2016, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.

Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 32 and 16 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 2, 6, 10 and 15 molecules, respectively.

Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 5

Dengue Fever Overview 6

Therapeutics Development 7

Dengue Fever - Therapeutics under Development by Companies 9

Dengue Fever - Therapeutics under Investigation by Universities/Institutes 12

Dengue Fever - Pipeline Products Glance 14

Dengue Fever - Products under Development by Companies 17

Dengue Fever - Products under Investigation by Universities/Institutes 20

Dengue Fever - Companies Involved in Therapeutics Development 22

Dengue Fever - Therapeutics Assessment 59

Drug Profiles 68

Dengue Fever - Dormant Projects 164

Dengue Fever - Discontinued Products 170

Dengue Fever - Product Development Milestones 171

Appendix 184





List of Tables

Number of Products under Development for Dengue Fever, H2 2016 17

Number of Products under Development for Dengue Fever - Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 23

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Investigation by Universities/Institutes, H2 2016 30

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 31

Dengue Fever - Pipeline by Abivax SA, H2 2016 32

Dengue Fever - Pipeline by Agilvax Inc, H2 2016 33

Dengue Fever - Pipeline by Altravax Inc, H2 2016 34

Dengue Fever - Pipeline by Biological Mimetics Inc, H2 2016 35

Dengue Fever - Pipeline by Bioneer Corp, H2 2016 36

Dengue Fever - Pipeline by Biotron Ltd, H2 2016 37

Dengue Fever - Pipeline by Codagenix Inc, H2 2016 38

Dengue Fever - Pipeline by Emergent BioSolutions Inc, H2 2016 39

Dengue Fever - Pipeline by Ennaid Therapeutics LLC, H2 2016 40

Dengue Fever - Pipeline by GeneSegues Inc, H2 2016 41

Dengue Fever - Pipeline by GlaxoSmithKline Plc, H2 2016 42

Dengue Fever - Pipeline by Globavir Biosciences Inc, H2 2016 43

Dengue Fever - Pipeline by Hawaii Biotech Inc, H2 2016 44

Dengue Fever - Pipeline by HSRx Group, H2 2016 45

Dengue Fever - Pipeline by Humabs BioMed SA, H2 2016 46

Dengue Fever - Pipeline by Immunotope Inc, H2 2016 47

Dengue Fever - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 48

Dengue Fever - Pipeline by Johnson & Johnson, H2 2016 49

Dengue Fever - Pipeline by Kineta Inc, H2 2016 50

Dengue Fever - Pipeline by Merck & Co Inc, H2 2016 51

Dengue Fever - Pipeline by Molplex Ltd, H2 2016 52

Dengue Fever - Pipeline by NanoViricides Inc, H2 2016 53

Dengue Fever - Pipeline by Novartis AG, H2 2016 54

Dengue Fever - Pipeline by NovaTarg Therapeutics Inc, H2 2016 55

Dengue Fever - Pipeline by Panacea Biotec Ltd, H2 2016 56

Dengue Fever - Pipeline by Plex Pharmaceuticals Inc, H2 2016 57

Dengue Fever - Pipeline by ProtInhi BV, H2 2016 58

Dengue Fever - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 59

Dengue Fever - Pipeline by Sarepta Therapeutics Inc, H2 2016 60

Dengue Fever - Pipeline by SIGA Technologies Inc, H2 2016 61

Dengue Fever - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 62

Dengue Fever - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 63

Dengue Fever - Pipeline by TechnoVax Inc, H2 2016 64

Dengue Fever - Pipeline by Themis Bioscience GmbH, H2 2016 65

Dengue Fever - Pipeline by VaxInnate Corp, H2 2016 66

Dengue Fever - Pipeline by Visterra Inc, H2 2016 67

Dengue Fever - Pipeline by VLP Therapeutics LLC, H2 2016 68

Assessment by Monotherapy Products, H2 2016 69

Number of Products by Stage and Target, H2 2016 71

Number of Products by Stage and Mechanism of Action, H2 2016 73

Number of Products by Stage and Route of Administration, H2 2016 75

Number of Products by Stage and Molecule Type, H2 2016 77

Dengue Fever - Dormant Projects, H2 2016 174

Dengue Fever - Dormant Projects (Contd..1), H2 2016 175

Dengue Fever - Dormant Projects (Contd..2), H2 2016 176

Dengue Fever - Dormant Projects (Contd..3), H2 2016 177

Dengue Fever - Dormant Projects (Contd..4), H2 2016 178

Dengue Fever - Dormant Projects (Contd..5), H2 2016 179

Dengue Fever - Discontinued Products, H2 2016 180





List of Figures

Number of Products under Development for Dengue Fever, H2 2016 17

Number of Products under Development for Dengue Fever - Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Products, H2 2016 26

Assessment by Monotherapy Products, H2 2016 69

Number of Products by Top 10 Targets, H2 2016 70

Number of Products by Stage and Top 10 Targets, H2 2016 70

Number of Products by Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Routes of Administration, H2 2016 74

Number of Products by Stage and Routes of Administration, H2 2016 74

Number of Products by Top 10 Molecule Types, H2 2016 76

Number of Products by Stage and Top 10 Molecule Types, H2 2016 76

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus